TB Alliance

New collaboration will develop, deliver needed childhood TB medicines

30 October 2013 (PARIS, FRANCE): In an effort to develop and deliver treatments for children with tuberculosis (TB)—answering a critical need in public health today—TB Alliance, a not-for-profit organization with the mission to develop better, faster-acting, and affordable drugs for TB, has entered into a collaboration with Svizera Europe, one of the leading global supply and distribution companies for TB treatments. The partnership aims to create and enable access to new medicines for childhood TB. Tuberculosis is among the top 10 killers of children and an estimated 500,000 children have TB, but many suspect the burden could be much higher.

Read More →

AusAID commits support to TB Alliance to advance new TB drugs

New York, USA: The Global Alliance for TB Drug Development (TB Alliance) has received a grant from the Australian Agency for International Development (AusAID) to support the advancement of the largest pipeline of potential new TB drugs. This one-year $2.5 million grant funds further development of urgently needed new TB treatments to combat the global epidemic, which is growing increasingly resistant to today’s available therapies. TB Alliance received this support as part of Australia’s first set of grants to fund new product development to treat diseases of poverty.

Read More →

TB Alliance launches interactive pipeline

TB Alliance and its partners manage the largest pipeline of potential new TB drugs and drug regimens in history. A newly launched web-based tool allows users to follow the progress of TB Alliance research and development programs, offering key information on each project, clinical trial, and experimental regimen undergoing development.

Read More →

GHIT leverages Japanese innovation in fight against TB

The Global Health Innovative Technology Fund (GHIT Fund), a new public-private partnership that’s bringing Japanese research and development (R&D) to the global fight against infectious disease, will announce at the 5th Tokyo International Conference on African Development (TICAD V) a series of historic agreements to screen compound libraries at Japanese pharmaceutical companies and research institutes for new treatments for malaria, tuberculosis, and other afflictions that prey mainly on the poorest of the poor.

Read More →

TB Alliance licenses late-stage TB program to CSIR-OSDD

TB Alliance, an international non-profit organization which develops better, faster-acting, and affordable TB drugs, has announced that it has granted a license to and is working with the Open Source Drug Discovery (OSDD) programme of Council of Scientific and Industrial Research (CSIR) to develop and commercialize a promising new tuberculosis (TB) regimen for use within India. CSIR is an Indian governmental institution, which provides scientific and industrial R&D that maximizes the economic, environmental, and societal benefits for the people of India.

Read More →

UNITAID and TB Alliance call for more action against childhood tuberculosis

In TB fight, children must be a priority – World TB Day March 24

Read More →

Improving the therapeutic potential of pyrazinamide

Pyrazinamide (PZA) is an incredibly important sterilizing agent in the treatment of tuberculosis and is considered responsible for reducing the duration of treatment from the previous 9-12 months, to the current short-course of 6 months produced by the standard regimen (HRZE).Beyond its contribution in the current  first-line regimen, the TB Alliance, through its ongoing novel regimen development program is finding that PZA is critical to any treatment shortening regimen, including those that contain newer agents currently in clinical development.  PZA has the ability to synergize with other drugs and this synergy drives the treatment-shortening potential of experimental regimens, such as PaMZ (PA-824 + moxifloxacin + pyrazinamide) currently under clinical development. However, resistance to PZA is on the rise, creating potential problems for PZA-containing regimens in development. Yet, there may be ways to circumvent this resistance. Investigating whether this is possible is the focus of a 1-year, $250,000 grant from the US NIH ACTG.

Read More →

TB Alliance receives grant from UNITAID to develop pediatric TB drugs

Grant to reshape market forces, catalyze development to improve treatment of childhood TB.

Read More →

TB Alliance and FIND announce collaboration to promote development of TB drugs and diagnostics

NEW YORK, NY/GENEVA, SWITZERLAND A new partnership announced today will increase efforts to coordinate the development of complementary novel tools to fight TB, including drug-resistant TB, and identify emerging drug resistance trends around the globe.

Read More →

TB Alliance to present research at ICAAC 2012

The TB Alliance and its partners will be presenting recent advances in TB research and development at the ICAAC 2012 conference. Posters and presentations will detail important findings from the The University of Auckland and TB Alliance’s lead preclinical TB drug candidate, the nitroimidazole, TBA-354.

Read More →

Page 5 of 6 · Total posts: 10

←First 4 5 6 Last→